CN118647618A - Rabeximod化合物 - Google Patents

Rabeximod化合物 Download PDF

Info

Publication number
CN118647618A
CN118647618A CN202280081094.2A CN202280081094A CN118647618A CN 118647618 A CN118647618 A CN 118647618A CN 202280081094 A CN202280081094 A CN 202280081094A CN 118647618 A CN118647618 A CN 118647618A
Authority
CN
China
Prior art keywords
compound
salt
rabeximod
rheumatoid arthritis
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280081094.2A
Other languages
English (en)
Chinese (zh)
Inventor
W·多尔比布朗
L·A·H·范平克斯特伦
R·E·斯廷达姆
J·尼博
M·I·贝特霍尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN118647618A publication Critical patent/CN118647618A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fire-Extinguishing Compositions (AREA)
CN202280081094.2A 2021-12-09 2022-12-08 Rabeximod化合物 Pending CN118647618A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21213418 2021-12-09
EP21213418.3 2021-12-09
PCT/EP2022/085060 WO2023104998A1 (en) 2021-12-09 2022-12-08 Rabeximod compounds

Publications (1)

Publication Number Publication Date
CN118647618A true CN118647618A (zh) 2024-09-13

Family

ID=78827545

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280081094.2A Pending CN118647618A (zh) 2021-12-09 2022-12-08 Rabeximod化合物

Country Status (8)

Country Link
US (1) US11643415B1 (https=)
EP (1) EP4444720A1 (https=)
JP (1) JP2024546098A (https=)
KR (1) KR20240115849A (https=)
CN (1) CN118647618A (https=)
AU (1) AU2022407139A1 (https=)
CA (1) CA3239544A1 (https=)
WO (1) WO2023104998A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230022880A (ko) * 2020-06-10 2023-02-16 사익손 아베 라벡시모드의 결정성 형태를 포함하는 경구 제형

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE527639C2 (sv) 2004-06-17 2006-05-02 Oxypharma Ab Alkylsubstituerade indolokinoxaliner
EA201500942A1 (ru) * 2013-03-15 2016-03-31 Виронова Херпес Аб ПРОТИВОВИРУСНЫЙ ИНДОЛО[2,3-b]ХИНОКСАЛИН
KR20230022880A (ko) 2020-06-10 2023-02-16 사익손 아베 라벡시모드의 결정성 형태를 포함하는 경구 제형

Also Published As

Publication number Publication date
CA3239544A1 (en) 2023-06-15
AU2022407139A1 (en) 2024-05-23
EP4444720A1 (en) 2024-10-16
KR20240115849A (ko) 2024-07-26
WO2023104998A1 (en) 2023-06-15
US11643415B1 (en) 2023-05-09
JP2024546098A (ja) 2024-12-17

Similar Documents

Publication Publication Date Title
US12419877B2 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
JP6447508B2 (ja) ３−（イミダゾ［１，２−ｂ］ピリダジン−３−イルエチニル）−４−メチル−Ｎ−｛４−［（４−メチルピペラジン−１−イル）メチル］−３−（トリフルオロメチル）フェニル｝ベンズアミドおよびその一塩酸塩の結晶形
US9809551B2 (en) Solid forms of Ivacaftor and processes for the preparation thereof
TWI815820B (zh) ２－（５－（４－（２－嗎啉乙氧基）苯基）吡啶－２－基）－ｎ－芐乙醯胺之固態形式
CN118647618A (zh) Rabeximod化合物
CN111971272A (zh) 柳氮磺吡啶盐组合物及其使用方法
US11267791B2 (en) Highly stable crystalline Eltrombopag monoethanolamine salt form D1
EP3315493A1 (en) Phenyl amino pyrimidine compound or polymorph of salt thereof
KR20200071090A (ko) 에다라본 염
CN102770416B (zh) 美他沙酮共晶体
WO2008108630A1 (en) Polymorphic forms of efavirenz
US20210122718A1 (en) Novel forms of fedratinib dihydrochloride
ES3059511T3 (en) Stable salt and crystal forms of 2-[3-({1-[2-(dimethylamino)ethyl]-2-(2,2-dimethylpropyl)-1h-1,3-benzodiazol-5-yl}sulfonyl)azetidin-1-yl]ethan-1-ol
RU2802964C2 (ru) Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида
HK40115548A (zh) 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式
RU2822220C2 (ru) Фармацевтические композиции для лечения муковисцидоза
JP2018515477A (ja) 免疫調節薬の新規な結晶形
NZ719970B2 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination